Safety and immune response kinetics of GRAd-COV2 vaccine : phase 1 clinical trial results
© 2022. The Author(s)..
Despite the successful deployment of efficacious vaccines and therapeutics, the development of novel vaccines for SARS-CoV-2 remains a major goal to increase vaccine doses availability and accessibility for lower income setting. We report here on the kinetics of Spike-specific humoral and T-cell response in young and old volunteers over 6 months follow-up after a single intramuscular administration of GRAd-COV2, a gorilla adenoviral vector-based vaccine candidate currently in phase-2 of clinical development. At all three tested vaccine dosages, Spike binding and neutralizing antibodies were induced and substantially maintained up to 3 months, to then contract at 6 months. Potent T-cell responses were readily induced and sustained throughout the study period, with only minor decline. No major differences in immune response to GRAd-COV2 vaccination were observed in the two age cohorts. In light of its favorable safety and immunogenicity, GRAd-COV2 is a valuable candidate for further clinical development and potential addition to the COVID-19 vaccine toolbox to help fighting SARS-CoV-2 pandemic.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
|---|---|
| Enthalten in: |
NPJ vaccines - 7(2022), 1 vom: 24. Sept., Seite 111 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 30.09.2022 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1038/s41541-022-00531-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM346696119 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM346696119 | ||
| 003 | DE-627 | ||
| 005 | 20231226032055.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41541-022-00531-8 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1155.xml |
| 035 | |a (DE-627)NLM346696119 | ||
| 035 | |a (NLM)36153335 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Agrati, Chiara |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Safety and immune response kinetics of GRAd-COV2 vaccine |b phase 1 clinical trial results |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 30.09.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2022. The Author(s). | ||
| 520 | |a Despite the successful deployment of efficacious vaccines and therapeutics, the development of novel vaccines for SARS-CoV-2 remains a major goal to increase vaccine doses availability and accessibility for lower income setting. We report here on the kinetics of Spike-specific humoral and T-cell response in young and old volunteers over 6 months follow-up after a single intramuscular administration of GRAd-COV2, a gorilla adenoviral vector-based vaccine candidate currently in phase-2 of clinical development. At all three tested vaccine dosages, Spike binding and neutralizing antibodies were induced and substantially maintained up to 3 months, to then contract at 6 months. Potent T-cell responses were readily induced and sustained throughout the study period, with only minor decline. No major differences in immune response to GRAd-COV2 vaccination were observed in the two age cohorts. In light of its favorable safety and immunogenicity, GRAd-COV2 is a valuable candidate for further clinical development and potential addition to the COVID-19 vaccine toolbox to help fighting SARS-CoV-2 pandemic | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Castilletti, Concetta |e verfasserin |4 aut | |
| 700 | 1 | |a Battella, Simone |e verfasserin |4 aut | |
| 700 | 1 | |a Cimini, Eleonora |e verfasserin |4 aut | |
| 700 | 1 | |a Matusali, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Sommella, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Sacchi, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Colavita, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Contino, Alessandra M |e verfasserin |4 aut | |
| 700 | 1 | |a Bordoni, Veronica |e verfasserin |4 aut | |
| 700 | 1 | |a Meschi, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Gramigna, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Barra, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Grassi, Germana |e verfasserin |4 aut | |
| 700 | 1 | |a Bordi, Licia |e verfasserin |4 aut | |
| 700 | 1 | |a Lapa, Daniele |e verfasserin |4 aut | |
| 700 | 1 | |a Notari, Stefania |e verfasserin |4 aut | |
| 700 | 1 | |a Casetti, Rita |e verfasserin |4 aut | |
| 700 | 1 | |a Bettini, Aurora |e verfasserin |4 aut | |
| 700 | 1 | |a Francalancia, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Ciufoli, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Vergori, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Vita, Serena |e verfasserin |4 aut | |
| 700 | 1 | |a Gentile, Michela |e verfasserin |4 aut | |
| 700 | 1 | |a Raggioli, Angelo |e verfasserin |4 aut | |
| 700 | 1 | |a Plazzi, Maria M |e verfasserin |4 aut | |
| 700 | 1 | |a Bacchieri, Antonella |e verfasserin |4 aut | |
| 700 | 1 | |a Nicastri, Emanuele |e verfasserin |4 aut | |
| 700 | 1 | |a Antinori, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Milleri, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Lanini, Simone |e verfasserin |4 aut | |
| 700 | 1 | |a Colloca, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Girardi, Enrico |e verfasserin |4 aut | |
| 700 | 1 | |a Camerini, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Ippolito, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Vaia, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Folgori, Antonella |e verfasserin |4 aut | |
| 700 | 1 | |a Capone, Stefania |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t NPJ vaccines |d 2016 |g 7(2022), 1 vom: 24. Sept., Seite 111 |w (DE-627)NLM273825623 |x 2059-0105 |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:2022 |g number:1 |g day:24 |g month:09 |g pages:111 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41541-022-00531-8 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 2022 |e 1 |b 24 |c 09 |h 111 | ||